Class / Patent application number | Description | Number of patent applications / Date published |
514115000 | N-C(=X)-N containing (X is chalcogen) | 8 |
20090215730 | Antineoplastic compounds and pharmaceutical compositions thereof - Chemical compounds derived by in silico molecular modelling, having a well defined structure suitable for the blocking of the phosphorylation event, through the specific interaction of the chemical with the Casein Kinase 2 enzyme substrate phosphorylation domain or it's neighbourhood. This invention comprises also the pharmaceutical compositions containing such compounds, and their use in the preparation of medicines or agents for the treatment of diseases or conditions related with neoplasic processes. | 08-27-2009 |
20110224174 | CREATINE ESTER ANTI-INFLAMMATORY COMPOUNDS AND FORMULATIONS - The present invention provides a creatine ester anti-inflammatory compound which may be received by animals and then metabolized into a biologically active form of creatine. The biologically active creatine inhibits the production of chemical mediators, released during an inflammatory response, which are important components in the inflammatory response and the inflammation and pain resulting from physical or chemical trauma to cells and tissue. | 09-15-2011 |
20110319366 | Plasma Carboxypeptidase B Inhibitors - Compounds of the following formula (I), for example: | 12-29-2011 |
20120101069 | HEMODIALYSIS AND PERITONEAL DIALYSIS SOLUTIONS COMPRISING ONE OR MORE CREATINE COMPOUNDS - The present invention relates to a haemodialysis solution or concentrate thereof comprising creatine compound(s) and the use of creatine compound(s) for preparing a dialysis solution or concentrate thereof. Furthermore, the present invention is directed to a method for preparing creatine-containing dialysis solutions and concentrates. In addition, the present invention is directed to a method for treating patients with dialysis dependent renal failure with creatine compounds and to provide a variety of significant health benefits and improvement of life quality parameters for dialysis patients. This is achieve by supporting and improving the physiological functions of the patients organs and cells via creatine compounds delivery to the patients, and by protecting organs and cells (specifically including blood cells) of these patients from deleterious effects of a variety of endogenous or exogenous cellular stressors that are linked to the disease state or to the clinical treatment modalities. Furthermore in peritoneal dialysis solutions creatine can be used as an osmotic agent preventing side effects caused by high glucose supplementation. | 04-26-2012 |
20130274230 | (2-UREIDOACETAMIDO)ALKYL DERIVATIVES AS FORMYL PEPTIDE RECEPTOR 2 MODULATORS - The present invention relates to (2-ureidoacetamido)alkyl derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of the N-formyl peptide receptor 2. | 10-17-2013 |
20140113884 | EPOXYEICOSATRIENOIC ACID ANALOGS AND METHODS OF MAKING AND USING THE SAME - Compounds and compositions comprising epoxyeicosatrienoic acid (EET) analogs that act as EET agonists and are useful as medications in the treatment of drug-induced nephrotoxicity, hypertension and other related conditions. Methods of making and using the compounds and compositions are further described. | 04-24-2014 |
20140256684 | USE OF AGONISTS OF FORMYL PEPTIDE RECEPTOR 2 FOR TREATING OCULAR INFLAMMATORY DISEASES - The present invention relates to a method for treating ocular inflammatory diseases in a subject in need of such treatment, which comprises administering a pharmaceutical composition comprising a therapeutically effective amount of at least one agonist of Formyl peptide receptor 2. | 09-11-2014 |
20140256685 | USE OF AGONISTS OF FORMYL PEPTIDE RECEPTOR 2 FOR TREATING DERMATOLOGICAL DISEASES - The present invention relates to a method for treating dermal inflammation and dermal diseases by local or systemic delivery, in a subject in need of such treatment, which comprises administering a pharmaceutical composition comprising a therapeutically effective amount of at least one agonist of Formyl peptide receptor 2 (FPR2). | 09-11-2014 |